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Summary
Background: Rifaximin	reduces	the	risk	of	overt	hepatic	encephalopathy	(HE)	and	is	
associated	with	significant	reductions	in	hospitalisations	and	30‐day	readmissions.
Aim: To	examine	the	outcomes	of	patients	listed	for	liver	transplantation	with	a	diag‐
nosis	of	HE	on	rifaximin	compared	to	those	naïve	to	the	drug.
Methods: Patient	records	of	those	listed	for	liver	transplantation	over	a	2‐year	pe‐
riod	were	retrospectively	reviewed.	Patients	were	included	if	they	had	at	least	two	
episodes	of	overt	HE	resulting	in	hospitalisation	or	were	encephalopathic	at	the	time	
of	assessment.
Results: Of	the	622	patients	listed	for	transplantation,	101	had	HE.	Sixty‐six	patients	
were	treated	with	rifaximin	and	35	were	naïve	at	listing.	The	use	of	concurrent	lactu‐
lose	was	not	significantly	different	between	groups.	Median	MELD	score	was	similar	
(15	[14‐16)]	rifaximin‐treated	and	16	[14‐18]	rifaximin‐naïve).	Patients	on	the	waiting	
list	treated	with	rifaximin	had	reduced	all‐cause	admissions,	episodes	of	spontaneous	
bacterial	peritonitis	and	variceal	bleeding.	Mean	length	of	stay	was	9	(95%	CI	6‐12)	
in	the	rifaximin‐treated	group	vs	14	days	(95%	CI	7‐21)	in	the	rifaximin‐naïve	group.	
Multivariate	regression	analysis	demonstrated	that	rifaximin	was	independently	as‐
sociated	with	an	increase	in	average	days	to	readmission	(adjusted	effect	estimate	71,	
95%	CI	3‐140	days)	and	reduced	likelihood	of	requirement	for	prioritisation	on	the	
waiting	list	(odds	ratio	0.29;	95%	CI	0.89‐0.93).
Conclusion: Rifaximin	prescribed	 for	HE	 in	patients	 listed	 for	 liver	 transplantation	
improved	outcomes	with	significant	reduction	in	admissions	related	to	spontaneous	
bacterial	peritonitis,	ascites	and	variceal	bleeding.
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1  | INTRODUC TION
The	onset	of	advanced	cirrhosis	brings	with	it	a	catalogue	of	com‐
plications	 affecting	 multiple	 organ	 systems	 and	 includes	 hepatic	
encephalopathy	 (HE),	 variceal	 bleeding,	 ascites	 and	 a	 propensity	
to	 developing	 infections	 such	 as	 spontaneous	 bacterial	 peritonitis	
which	can	lead	to	the	rapid	onset	of	renal	failure	and	metabolic	dis‐
array.	Patients	may	progress	to	develop	acute‐on‐chronic	liver	fail‐
ure	(ACLF)	and	the	associated	morbidity	and	mortality	is	high.	These	
patients	 require	 frequent	 hospitalisation1	 often	 necessitating	 high	
dependency	or	 intensive	care	and	present	a	 significant	healthcare	
and	resource	burden.2	Without	access	to	 liver	transplantation,	the	
outlook	is	bleak.3
The	development	of	HE	in	both	its	covert4	and	overt	forms3,5 
confers	a	poor	prognosis.	The	1‐year	mortality	 following	a	diag‐
nosis	 of	 cirrhosis	 in	 the	 absence	 of	 any	 evidence	 of	 decompen‐
sation	 is	 approximately	 17%	 but	 approaches	 64%	 following	 the	
development	of	overt	HE.6	The	non‐absorbable	antibiotic	 rifaxi‐
min	reduces	the	risk	of	recurrence	of	overt	HE	and	the	need	for	
hospitalisation.7	Whilst	the	specific	mechanism	of	action	of	rifaxi‐
min	remains	to	be	elucidated,	it	has	been	postulated	to	reduce	cir‐
culating	levels	of	gut‐derived	endotoxins8	resulting	from	bacterial	
translocation.9	 In	 clinical	 practice,	 treatment	 with	 rifaximin	 has	
been	associated	with	significant	reductions	in	hospitalisation,	bed	
days	(including	critical	care),	emergency	department	attendances	
and	30‐day	readmissions.10,11	However,	there	is	a	paucity	of	data	
on	the	impact	of	rifaximin	on	outcomes	in	patients	with	end‐stage	
liver	disease.
The	aim	of	this	study	was	to	examine	the	outcomes	of	patients	
with	advanced	cirrhosis	listed	for	liver	transplantation	at	a	large	ter‐
tiary	 referral	 centre	with	 a	 diagnosis	 of	HE	 at	 listing	 treated	with	
rifaximin	compared	to	those	naïve	to	the	drug.	The	primary	objective	
was	to	compare	the	frequency	and	duration	of	all‐cause	emergency	
hospital	admissions.	Secondary	objectives	included	incidence	of	in‐
fection	and	admissions	related	to	complications	of	cirrhosis,	admis‐
sions	 to	 critical	 care,	 requirement	 for	prioritisation	on	 the	waiting	
list	and	mortality.
2  | MATERIAL S AND METHODS
2.1 | Study design and setting
The	 patient	 records	 of	 622	 patients	with	 confirmed	 cirrhosis	 (the	
diagnosis	of	cirrhosis	was	confirmed	by	a	combination	of	a	 least	2	
modalities:	clinical,	biochemical,	 radiological	and	histopathological)	
who	were	listed	for	liver	transplantation	at	King's	College	Hospital	
NHS	Foundation	Trust	over	a	2‐year	period	[1st	January	2014	–	31st	
January	2016]	were	retrospectively	reviewed.
2.2 | Participants
Patients	were	included	if	they	had	at	least	two	historic	episodes	of	
overt	HE	resulting	in	hospitalisation	or	were	overtly	encephalopathic	
at	 the	 time	of	 assessment.	Patients	under	 the	 age	of	18	were	ex‐
cluded	from	the	study.
2.3 | Data collection
Information	 collected	 included	patient	 demographics,	 aetiology	of	
liver	disease,	Child	Pugh	Turcotte	score,12	Model	for	End‐stage	Liver	
Disease	(MELD)	score13	at	the	time	of	assessments,	United	Kingdom	
End‐stage	Liver	Disease	(UKELD)	score,	maximum	grade	of	HE	(de‐
fined	using	 the	West	Haven	criteria),14 blood ammonia concentra‐
tion	(venous),	concurrent	lactulose	therapy,	medical	co‐morbidities,	
emergency	admission	whilst	on	the	waiting	list	including	admissions	
to	 high	 dependency	 and	 intensive	 care	 beds,	 requirement	 for	 pri‐
oritisation	 (UKELD	 score	 ≥63),	 duration	 on	 the	 waiting	 list	 (days)	
and	mortality	 on	 the	waiting	 list.	 Elective	 admissions,	 such	 as	 for	
large	 volume	 paracentesis	 were	 excluded	 unless	 the	 paracentesis	
was	complicated	 (defined	as	necessitating	a	hospital	admission	for	
greater	than	24	hours)	which	may	occur	for	example	due	to	spon‐
taneous	 bacterial	 peritonitis,	 acute	 kidney	 injury	 or	 electrolyte	
disturbance.
2.4 | Statistical methods
The	 primary	 outcome	was	 defined	 as	 the	 number	 of	 days	 to	 all	
cause	 readmission	on	 the	 transplant	waiting	 list.	Secondary	out‐
comes	evaluated	included	requirement	for	prioritisation,	hospital	
admissions	with	sepsis,	variceal	bleeding,	ascites	and	hepatic	en‐
cephalopathy,	 length	 of	 hospital	 stay,	 intensive	 care	 admissions,	
length	 of	 intensive	 care	 stay	 and	 mortality	 on	 the	 waiting	 list.	
Normality	testing	was	undertaken	on	all	continuous	clinical	and	bi‐
ochemical	data	using	the	D'Agnostino‐Pearson	omnibus	normality	
test.	Normally	distributed	data	are	presented	as	mean	with	95%	
CIs	 and	 non‐normally	 distributed	 data	 as	median	 and	 interquar‐
tile	 range.	Univariate	 statistical	 analysis	of	non‐normally	distrib‐
uted	unpaired	data	was	completed	using	the	Mann–Whitney	test	
and	 analysis	 of	 normally	 distributed	 data	 using	 unpaired	 t	 tests	
with	 Welch's	 correction	 assuming	 unequal	 standard	 deviations.	
Categorical	 variables	 are	 expressed	 as	 number	 and	 proportion	
and	compared	using	 the	X2	 test	or	Fisher's	exact	 test,	 as	appro‐
priate.	 Hospital	 admission	 data	 were	 presented	 as	 annualised	
rates.	 Multivariate	 linear	 regression	 analysis	 was	 performed	 on	
admission	and	complication	data	(related	to	sepsis,	acute	variceal	
hemorrhage,	encephalopathy	and	complications	of	ascites)	identi‐
fied	as	the	dependent	variable.	Binary	logistic	regression	analysis	
was	 subsequently	 performed	with	 requirement	 for	 prioritisation	
on	the	transplant	waiting	 list	 (yes/no)	as	the	dependent	variable.	
Forward	selection	was	used	to	select	independent	variables	within	
the	regression	models	with	P	<	0.1;	we	also	included	variables	con‐
sidered	 by	 subject	 knowledge	 or	 literature	 (ie	 lactulose	 use	 and	
MELD	 score)	 to	 be	 associated	with	 hospital	 readmission	 in	 end‐
stage	 chronic	 liver	 disease.	 Univariate	 and	 regression	 analyses	
were	performed	using	IBM	spss	Statistics	24	for	Mac.	A	P < 0.05 
was	considered	to	be	statistically	significant.
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3  | RESULTS
3.1 | Patient demographics
Of	 the	 622	 adult	 patients	 listed	 for	 transplantation,	 101	 were	
listed	with	HE.	Sixty‐six	patients	were	treated	with	rifaximin	and	
35	were	naïve.	There	was	a	male	preponderance	 in	both	groups	
and	 alcohol‐related	 liver	 disease	 was	 the	 most	 common	 aetiol‐
ogy.	 The	 rifaximin‐treated	 group	was	marginally	 older	mean	 age	
55	vs	49	(mean	difference	5.85	years	[95%	CI	0.72‐10.98]).	Organ	
severity	 scores	were	 similar;	mean	MELD	 score	was	 15	 (95%	CI	
14‐16)	in	the	rifaximin	cohort	and	16	(95%	CI	14‐18)	in	the	naïve	
[mean	 difference	 −1.1	 (95%	 CI	 −3.49‐1.38)].	 Mean	 Child‐Pugh	
Turcotte	 score	was	 10	 (95%	CI	 9.4‐10.2)	 in	 the	 rifaximin	 cohort	
and	10	(95%	CI	9.7‐10.9)	in	the	naïve	(mean	difference	−0.52	[95%	
CI	−1.24‐0.21]).	 82%	of	 those	on	 rifaximin	 and	71%	of	 those	on	
placebo	were	on	concurrent	 lactulose	therapy	(P	=	0.26).	Fifteen	
percent	 of	 the	 rifaximin	 cohort	 (10/66)	 were	 on	 ciprofloxacin	
prophylaxis	 (500	mg	 once	 daily)	 and	 20%	 of	 the	 rifaximin‐naive	
cohort	 (7/35)	 were	 on	 ciprofloxacin	 prophylaxis	 (500	 mg	 once	
daily)	for	primary	or	secondary	prophylaxis	of	spontaneous	bacte‐
rial	peritonitis;	this	was	not	statistically	significantly	different	be‐
tween	the	groups	(P	=	0.58).	The	mean	duration	on	the	waiting	list,	
the	maximum	grade	of	encephalopathy	at	listing	and	the	baseline	
venous	ammonia	levels	did	not	differ	between	those	on	rifaximin	
and	those	naïve	to	the	drug.	Body	Mass	Index	(BMI)	and	the	num‐
ber	of	medical	co‐morbidities	at	the	time	of	transplant	assessment	
was	similar	across	the	treatment	groups.	The	patient	demograph‐
ics	are	summarised	in	Table	1.
3.2 | Clinical outcomes
On	 univariate	 analysis,	 rifaximin‐treated	 patients	 had	 reduced	 all‐
cause	admissions	(elective	admissions	were	excluded)	on	the	waiting	
list	2.75	vs	6.30	 (mean	difference	−3.55	[95%	CI	−6.545	to	−0.56]	
admissions	per	 year).	Admissions	with	 episodes	of	 sepsis	 per	 year	
were	similar	between	groups	0.84	vs	1.81	 (mean	difference	−0.97	
[95%	 CI	 −2.27‐0.33]	 admissions	 per	 year).	 Admissions	 related	 to	
complications	 of	 large	 volume	 ascites	 including	 spontaneous	 bac‐
terial	 peritonitis,	 hepatorenal	 syndrome	 and	 metabolic	 disarray	
were	 reduced	 in	 the	 rifaximin‐treated	 patients	mean	0.77	 vs	 2.47	
(mean	difference	−1.70	[95%	CI	−2.99	to	−0.41]	admissions	per	year).	
Rifaximin‐treated	patients	had	a	reduced	requirement	for	admission	
with	acute	variceal	bleeding	per	year	mean	0.14	vs	1.03	[mean	dif‐
ference	−0.89	(95%	CI	−1.60	to	−0.18)	admissions	per	year].	Patients	
were	less	likely	to	warrant	prioritisation	on	the	transplant	waiting	list	
(defined	during	this	study	as	having	a	UKELD	score	≥63);	odds	ratio	
0.34	(95%	CI	013‐0.90).
Mean	 length	of	hospital	 stay	 (8.69	vs	14.43	days,	mean	differ‐
ence	−5.74	[95%	CI	−12.23	to	0.76]	days)	and	mean	length	of	inten‐
sive	care	unit	stay	(1.09	vs	2.49	days,	mean	difference	−1.40	[95%	
CI	−3.76	to	0.97]	days)	were	not	significantly	different	in	rifaximin‐
treated	 and	 rifaximin‐naïve	 groups.	 Interestingly,	 admissions	 with	
acute	overt	HE	did	not	significantly	differ	and	neither	was	mortality	
on	the	waiting	list	impacted	upon	despite	the	reduced	rate	of	vari‐
ceal	bleeding,	complications	of	ascites	and	all‐cause	hospitalisation	
in	the	rifaximin‐treated	cohort.	The	overall	waiting	list	mortality	in	
this	study	was	13.86%.	Clinical	outcomes	are	summarised	in	Table	2	
and	Figure	1.
Multivariate	linear	regression	analysis	with	days	to	readmission	
(related	 to	 complications	 of	 ascites,	 variceal	 bleeding,	 hepatic	 en‐
cephalopathy	or	sepsis)	defined	as	the	dependent	variable	demon‐
strated	that	rifaximin	treatment	was	independently	associated	with	
increased	length	to	all‐cause	readmission	whilst	on	the	liver	trans‐
plant	waiting	 list;	adjusted	effect	estimate	71	 (95%	CI	3‐140	days)	
when	adjusting	 for	 age,	 sex,	BMI,	 disease	 severity	 score	 and	 con‐
comitant	 lactulose	 use.	 Similarly,	 rifaximin	 use	was	 independently	
TA B L E  1  Baseline	patient	demographics	at	transplant	listing
Variable
Rifaximin 
treated  
n = 66
Rifaximin 
naïve  
n = 35 P value 
Age	[mean	(95%	CI)] 55	(52‐58) 49	(45‐53) 0.007
Male	gender	(%) 48	(73) 22	(63) ns
BMI	[mean	(95%	CI)	kg/m2] 27.7 
(26.3‐
29.1)	
26.0	
(24.6‐
27.4)
ns
Concurrent	lactulose	n	(%)	 54	(82) 25	(71) ns
Duration	on	waiting	list	
[mean	(95%	CI)]
185 
(149‐221)
166	
(109‐223)
ns
Maximum	grade	of	HE	[mean	
(95%	CI)]
2	(1.7‐2.3) 2	(1.8‐2.2) ns
Organ	Severity	Score
MELD	score	[mean	(95%	
CI)]
15	(14‐16) 16	(14‐18) ns
	UKELD	score	[mean	(95%	
CI)]
56	
(55‐57)
56	(55‐58) ns
Child‐Pugh‐Turcotte	Score	
[mean	(95%	CI)]
10 
(9.6‐10.4)
10 
(9.4‐10.6)
ns
Aetiology	of	Liver	Disease
Alcohol‐related	cirrhosis	
n	(%)
30	(46) 11	(31) ns
	NASH	cirrhosis	n	(%) 2	(3) 2	(5) ns
HCV	cirrhosis	n	(%) 11	(17) 7	(19) ns
	HBV	cirrhosis	n	(%)	 0	(0) 1	(3) ns
Autoimmune	cirrhosis	n	(%) 12	(19) 9	(24) ns
	HCC	n	(%) 7	(11) 1	(3) ns
Cryptogenic	cirrhosis	n	(%) 6	(9) 4	(11)	 ns
Abbreviations:	CI:	confidence	interval;	HE:	hepatic	encephalopathy;	
NASH:	non‐alcoholic	steatohepatitis;	HBV:	hepatitis	B;	HCV:	hepatitis	
C;	HCC:	hepatocellular	carcinoma;	MELD:	model	for	end‐stage	liver	
disease;	UKELD:	UK	end‐stage	liver	disease.
Spontaneous	bacterial	peritonitis	and	urinary	tract	infections	are	the	
commonest	bacterial	infections	complicating	cirrhosis‐associated	
immune	dysfunction.
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associated	 with	 a	 significant	 reduction	 in	 the	 number	 of	 hospital	
admissions	relating	to	variceal	bleeding,	complications	of	ascites	and	
all‐cause	 hospital	 readmission	 (Table	 2).	 Binary	 logistic	 regression	
was	performed	to	assess	requirement	for	prioritisation	(UKELD	≥63)	
on	the	liver	transplant	waiting	list	and	demonstrated	that	rifaximin	
treatment	was	independently	associated	with	a	lower	likelihood	of	
requirement	 for	prioritisation	 (odds	 ratio	0.29	 [95%	CI	0.09‐0.93])	
when	adjusting	 for	 age,	 sex,	BMI,	 disease	 severity	 score	 and	 con‐
comitant	lactulose	use.
Of	the	31	patients	who	were	admitted	due	to	suspected	sep‐
sis,	 a	 source	 of	 infection	 was	 only	 confirmed	 in	 cultures	 in	 12	
(38.7%)	 patients	 (13/66	 [19.7%]	 on	 rifaximin	 vs	 18/35	 [51.4%]	
in	 those	 who	were	 not	 treated	 with	 rifaximin;	 P	 =	 0.016).	 This	
included	 three	episodes	of	pneumonia,	 three	episodes	of	 spon‐
taneous	bacterial	peritonitis,	 three	episodes	of	bacteremia,	 two	
cases	of	cellulitis,	one	case	of	infective	endocarditis	and	one	case	
with	 a	 breast	 abscess.	 Organisms	 cultured	 included	 vancomy‐
cin‐resistant	enterococcus,	escheria	coli,	 klebsiella	pneumoniae,	
streptococcus	 viridans,	 coagulase	 negative	 staphylococcus	 au‐
reus	and	Clostridium difficile	(rifaximin‐naïve	patient).	Within	our	
cohort,	there	were	no	documented	cases	of	C difficile	infection	in	
patients	taking	rifaximin.
4  | DISCUSSION
This	 retrospective	 ‘real‐world’	 cohort	 study	 examining	 the	 liver	
transplant	waiting	list	outcomes	of	101	patients	listed	with	overt	HE	
shows	that	those	who	were	prescribed	rifaximin	for	the	recurrence	
of	overt	HE	had	improved	outcomes	on	the	waiting	list	with	a	signifi‐
cant	reduction	in	all‐cause	hospital	admissions,	an	increased	time	to	
hospital	readmission	and	reduced	requirement	for	listing	prioritisa‐
tion	compared	to	those	naïve	to	rifaximin.
There	 is	now	a	 robust	evidence	base	 to	 support	 rifaximin	as	a	
beneficial	 adjunctive	 therapy	 to	 lactulose	 in	 the	prevention	of	 re‐
current	episodes	of	overt	HE,7	 reducing	 the	 risk	of	hospitalisation	
and	lowering	inpatient	length	of	stay	and	healthcare	resource	utilisa‐
tion.10,11	Furthermore,	it	has	been	shown	to	improve	health‐related	
quality	of	life	in	patients	with	cirrhosis	and	overt	HE	in	remission15 
and	has	been	demonstrated	to	be	safe	and	well	tolerated	in	patients	
for	long‐term	maintenance	of	remission	from	overt	HE.16	However,	
‘real	world’	data	on	the	impact	of	rifaximin	on	the	outcomes	of	pa‐
tients	with	advanced	cirrhosis	remains	sparse	and	there	are	no	data	
on	its	impact	on	the	outcomes	of	patients	listed	for	liver	transplan‐
tation.	Indeed,	the	pivotal	Bass	trial7	excluded	patients	with	a	MELD	
score	of	>25	with	one‐fifth	of	the	included	patients	having	a	MELD	
Outcome
Univariate analysis[unadjusted effect 
estimate (95% CI), P value]
Multivariate analysis 
[confounder-adjusted effect 
estimate (95% CI), P value]
All‐cause	
admissions/year
−3.55 (-6.55 – -0.55), P=0.021 −3.10 (-6.00 – -0.20), P=0.037
Days	to	readmission	 +82 (48 – 117), P=0.025 +71 (3 – 139), P=0.040
Admissions	with	
sepsis/year
−0.97	(‐2.27	–	0.33),	P=ns −0.49	(‐1.75	–	0.98),	P=ns
Admissions	with	
complications	of	
ascites	including	
SBP/year	
−1.70 (-3.00 – -0.4), P=0.010 −1.77 (-3.07 – -0.47), P=0.008
Admissions	with	
acute variceal 
bleeding/year	
−0.89 (-1.59 – -0.19), P=0.014 −0.81 (-1.52 – -0.10), P=0.026
Admissions	with	
overt hepatic 
encephalopathy/
year 
−0.01	(‐0.81	–	0.79),	P=ns −0.07	(‐0.95	–	0.81),	P=ns
Length	of	hospital	
stay	(days)	
−5.74	(‐12.5	–	1.06),	P=ns −6.35	(‐12.85	–	0.15),	P=ns
Intensive	care	
admissions/year
−0.46	(‐1.66	–	0.74),	P=ns −0.04	(‐1.18	–	1.10),	P=ns
Length	of	intensive	
care	stay	(days)
−1.40	(‐3.80	–	1.20),	P=ns −1.15	(‐3.48	–	1.18),	P=ns
Requirement	for	
prioritisation	on	
the	waiting	list	
(odds	ratio)	
0.34 (0.13 – 0.90), P=0.03 0.29 (0.09 – 0.93), P=0.037
Mortality	on	the	
waiting	list	(odds	
ratio)	
0.66	(0.21	–	2.10),	P=ns 0.40	(0.11	–	1.48),	P=ns
TA B L E  2  Clinical	outcomes	from	
univariate	and	multivariate	analyses	
comparing	rifaximin‐treated	and	rifaximin‐
naïve	patients	on	the	liver	transplant	
waiting	list.
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score	of	≤10,	two‐thirds	with	a	MELD	score	between	11	and	18	and	
<10%	with	 a	MELD	between	 19	 and	 24.	We	 therefore	 set	 out	 to	
determine	the	impact	of	treatment	with	rifaximin	in	patients	listed	
with	overt	HE	whilst	they	were	on	the	liver	transplant	waiting	list	at	
a	large	UK	transplant	centre.
One	of	the	strengths	of	this	study	was	that	whilst	a	 large	pro‐
portion	of	the	patients	included	in	this	study	had	alcohol‐related	cir‐
rhosis	because	they	had	been	abstinent	for	at	least	6	months	prior	
to	 listing,	active	alcohol	 intake	was	not	a	confounder	 in	 this	study	
as	it	has	been	in	other	‘real‐world’	studies10,11	where	it	was	difficult	
to	determine	if	abstinence	from	alcohol	or	rifaximin	was	the	major	
driver	in	the	improved	outcomes	in	this	cohort	of	patients.
Patients	with	 advanced	 cirrhosis	 are	 susceptible	 to	 unplanned	
emergency	hospitalisations	 for	a	variety	of	 reasons,	 including	sus‐
ceptibility	 to	 infection,17	 overt	 HE,5	 acute	 kidney	 injury,	 acute	
variceal	 bleeding,	 electrolyte	 disturbance,	 large	 volume	 ascites,	
spontaneous	bacterial	peritonitis,	falls,	malnutrition	and	sarcopenia.	
These	patients	frequently	progress	to	requiring	high	dependency	or	
intensive	care	support2,18	and	may	at	any	time	progress	to	develop‐
ing	ACLF.19,20
Infection	is	the	leading	cause	of	death	in	patients	with	end‐stage	
liver	disease	and	confers	 a	 fourfold	 increased	mortality	 compared	
to	non‐infected	patients;	30%	of	patients	die	within	1	month	after	
infection	and	another	30%	die	by	1	year	with	spontaneous	bacterial	
peritonitis	and	urinary	tract	infections	representing	the	commonest	
bacterial	infections	complicating	cirrhosis.21	Systemic	inflammation	
and	infection	are	also	major	drivers	of	episodes	of	HE22,23 and have 
been	 implicated	 in	 patients	 admitted	 with	 advanced	 HE	 (grades	
3	 and	 4)	 regardless	 of	 blood	 ammonia	 levels	 and	 MELD	 score.24 
Systemic	 inflammation	 is	also	 likely	 to	be	 the	single	biggest	driver	
for	the	development	of	ACLF.	In	the	CANONIC	study	patients	with	
acute	decompensation	of	cirrhosis	without	ACLF	showed	very	high	
baseline	 levels	of	 inflammatory	cytokines,	markers	of	systemic	ox‐
idative	stress	and	circulatory	dysfunction.	Moreover,	patients	with	
ACLF	showed	significantly	higher	levels	of	these	markers	than	those	
without	 ACLF.25	 It	 therefore	 follows	 that	 if	 patients	 in	 this	 study	
treated	with	rifaximin	have	reduced	all‐cause	unplanned	hospitalisa‐
tions	and	episodes	of	spontaneous	bacterial	peritonitis	that	rifaximin	
is	 reducing	 systemic	 inflammation	 and/or	 the	 susceptibility	 to	 de‐
veloping	infection.26	Indeed,	it	has	been	shown	that	rifaximin	does	
reduce	systemic	endotoxin	levels	and	this	is	likely	to	be	linked	to	a	
change	in	the	function	rather	than	composition	of	the	gut	microbi‐
ome	which	we	 know	 exhibits	 dysbiosis	 in	 patients	with	 advanced	
cirrhosis.8,27	 Indeed,	a	 recent	systematic	 review	and	meta‐analysis	
examining	 the	 impact	 of	 rifaximin	on	 the	 development	 of	 sponta‐
neous	bacterial	peritonitis	 showed	 that	 rifaximin	may	be	effective	
in	preventing	spontaneous	bacterial	peritonitis	in	patients	with	cir‐
rhosis	 and	 ascites	 compared	 to	 systemically	 absorbed	 antibiotics	
and compared to placebo.9	Another	retrospective	study	examining	
145	patients	with	cirrhosis	showed	rifaximin	treatment	was	signifi‐
cantly	associated	with	prolonged	overall	survival	and	reduced	risks	
of	 spontaneous	 bacterial	 peritonitis,	 variceal	 bleeding	 and	 recur‐
rent	HE.28	A	further	randomised	study	of	rifaximin	vs	placebo	also	
showed	 that	 rifaximin	 prevented	 the	 development	 of	 hepatorenal	
syndrome	which	in	many	cases	develops	in	association	with	sponta‐
neous	bacterial	peritonitis.29	Our	cohort	of	transplant‐listed	patients	
with	decompensated	cirrhosis	corroborates	 these	findings	with	an	
associated	reduction	 in	hospital	 readmission	with	complications	of	
ascites,	including	spontaneous	bacterial	peritonitis	and	hepatorenal	
syndrome	independently	associated	with	rifaximin	use.
F I G U R E  1  A,	All‐cause	admissions	
per	year	on	the	liver	transplant	waiting	
list	(mean	and	standard	deviation).	B,	
Admissions	with	variceal	bleeding	per	year	
on	the	liver	transplant	waiting	list	(mean	
and	standard	deviation).	C,	Admissions	
with	complications	of	ascites	(elective	
admissions	for	large	volume	paracentesis	
excluded)	including	spontaneous	bacterial	
peritonitis,	hepatorenal	syndrome	and	
metabolic	disarray	(mean	and	standard	
deviation).	D,	Admissions	with	sepsis	per	
year	on	the	liver	transplant	waiting	list	
(mean	and	standard	deviation)
Rifaximin Naive
P = 0.021
P = 0.010 P = 0.141
P = 0.014
0
5
10
15
20
Annualised all-cause admissions
Ad
m
iss
io
ns
 p
er
 y
ea
r
Rifaximin Naive
0
2
4
6
8
Admissions with ascitic complications
Ad
m
iss
io
ns
 p
er
 y
ea
r
Rifaximin Naive
0
2
4
6
Admissions with sepsis
Ad
m
iss
io
ns
 p
er
 y
ea
r
Rifaximin Naive
0
1
2
3
4
5
Variceal bleeding admissions
Ad
m
iss
io
ns
 p
er
 y
ea
r
(A) (B)
(C) (D)
6  |     SALEHI Et AL.
Our	 data	 also	 show	 that	 rifaximin	 independently	 led	 to	 a	 sig‐
nificant	 reduction	 in	 episodes	 of	 acute	 variceal	 bleeding	 on	 the	
transplant	waiting	list.	Patients	with	cirrhosis	and	portal	hyperten‐
sion	listed	for	transplantation	invariably	have	severe	portosystemic	
shunting	with	reverse	flow	in	the	portal	vein	and	recanalisation	of	
the	 umbilical	 vein.	 Furthermore,	 they	 have	 small	 bowel	 bacterial	
overgrowth,	 gut	 dysbiosis	 and	 increased	 gut	 permeability	 all	 con‐
tributing	 to	 bacterial	 translocation,	 endotoxemia	 and	 systemic	 in‐
flammation.30,31	This	 pathological	 process	has	been	demonstrated	
to	 alter	 the	 hemodynamic	 circulation	 and	 could	 increase	 portal	
pressure.	Rifaximin	may	 therefore	provide	a	 therapeutic	option	 to	
prevent	portal	hypertension‐related	bleeding	by	reducing	bacterial	
translocation	 and	 endotoxin	 levels.	 However,	 a	 recent	 small	 ran‐
domised	 controlled	 trial	 reported	 that	 4	weeks	 of	 treatment	with	
rifaximin	did	not	reduce	the	hepatic	venous	pressure	gradient	or	im‐
prove	systemic	hemodynamics	in	patients	with	cirrhosis	and	ascites.	
Furthermore,	 rifaximin	 did	 not	 affect	 glomerular	 filtration	 rate	 or	
levels	of	vasoactive	hormones.32
Surprisingly,	 patients	 treated	with	 rifaximin	 did	 not	 have	 a	 re‐
duction	 in	 emergency	 encephalopathy‐related	 admissions	 per	
se.	However,	 overall	 the	 absolute	mean	 number	 of	 admissions	 at‐
tributed	specifically	to	HE	per	year	was	low	(1.00	[95%	CI	0.46‐1.54]	
admissions	per	year	in	the	rifaximin	group	vs	0.98	[95%	CI	0.25‐1.73]	
in	the	naïve	group)	and	patients	listed	for	liver	transplantation	for	HE	
invariably	had	severe	and	treatment‐refractory	encephalopathy.	It	is	
also	important	to	say	that	patients	with	admissions	for	falls,	sepsis	
and	bleeding	often	developed	HE	during	that	admission	so	a	reduc‐
tion	in	all‐cause	admissions	on	rifaximin	indirectly	reduced	the	like‐
lihood	of	developing	HE.	There	was	also	no	difference	in	mortality	
although	overall	 the	transplant	waiting	 list	mortality	 in	this	cohort	
was	 low	at	13.89%	so	more	patients	would	need	to	have	been	 in‐
cluded	to	detect	a	mortality	difference.	Nevertheless,	patients	who	
deteriorate	whilst	 on	 the	waiting	 list	may	 require	prioritisation	 (in	
this	study	this	was	when	their	UKELD	score	reached	63	or	above).	
Patients	treated	with	rifaximin	were	less	likely	to	require	the	need	
for	prioritisation	in	this	study	and	therefore	this	may	have	also	had	
a	bearing	on	any	perceivable	mortality	difference.	Where	this	study	
falls	 short,	however,	 is	 that	we	were	unable	 to	determine	 in	many	
cases	 the	 precise	 duration	 of	 rifaximin	 therapy	 prior	 to	 being	 re‐
ferred	and	listed	for	transplantation	as	many	patients	were	tertiary	
referrals	 from	other	centres	where	we	could	not	access	 this	 infor‐
mation.	There	is	no	doubt	that	some	smaller	centres	at	that	time	did	
not	have	the	resources	or	access	 to	prescribe	the	drug	which	was	
licensed	in	January	2013	in	the	UK	and	approved	by	NICE	in	March	
2014.
This	study	revealed	an	independent	association	of	rifaximin	use	
with	 a	mean	 increase	 of	 71	 days	 to	 hospital	 readmission	with	 3.1	
admissions	per	year	avoided	with	a	significant	impact	on	healthcare	
resource	utilisation.	We	did	not	observe	a	significant	difference	 in	
hospital	bed	days,	8	in	the	rifaximin	group	vs	14	in	the	naïve	group	
(mean	effect	estimate	−6	[95%	CI	−12.23	to	0.76]	days)	and	intensive	
care	bed	days,	1	 in	the	rifaximin	group	vs	2	 (mean	effect	estimate	
−1.40	 [95%	CI	 −3.76	 to	 0.97]	 days)	 in	 the	 naïve	 group.	Moreover,	
recently	 published	 ‘real‐world’	 studies	 have	 shown	 that	 treatment	
with	rifaximin	was	associated	with	a	reduction	in	length	of	hospital	
stay	and	provides	good	value	for	money	in	terms	of	health	econom‐
ics	and	resource	utilisation.10,11
In	summary,	rifaximin	prescribed	for	the	recurrence	of	overt	HE	
in	patients	listed	for	liver	transplantation	improved	outcomes	on	the	
waiting	list	with	a	significant	reduction	in	hospital	admissions	related	
to	decompensation,	variceal	bleeding	and	complications	of	ascites.	
There	was	 a	 reduced	 requirement	 for	 prioritisation	of	 patients	on	
the	waiting	 list	 in	patients	 treated	with	rifaximin	and	an	 increased	
time	 to	hospital	 readmission.	This	 study	provides	 ‘real‐world’	data	
that	demonstrates	the	potential	value	of	rifaximin	in	reducing	hos‐
pital	 admissions	 and	 length	 of	 stay	 within	 the	 advanced	 cirrhotic	
population	awaiting	liver	transplantation.	At	this	point,	however,	the	
data	should	not	be	interpreted	as	a	reason	to	change	clinical	practice	
but	 should	act	as	a	catalyst	 for	 further	prospective	studies	 in	 this	
patient	group.
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